07:00 , Apr 22, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Ligase IV, DNA, ATP-dependent (LIG4); BTB domain containing 2 (BTBD2); high mobility group AT-hook 2 (HMGA2); regulator of telomere elongation helicase 1 (RTEL1);...
07:00 , Jun 12, 2006 |  BC Week In Review  |  Company News

Oxis sales and marketing update

OXIS launched a series of reagents and antibodies to detect and measure high motility group A2 ( HMGA2 ) protein in tissue samples. HMGA2 is a marker for aggressive early stage breast cancer, OXIS said....